Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11516479rdf:typepubmed:Citationlld:pubmed
pubmed-article:11516479lifeskim:mentionsumls-concept:C0026844lld:lifeskim
pubmed-article:11516479lifeskim:mentionsumls-concept:C1135918lld:lifeskim
pubmed-article:11516479lifeskim:mentionsumls-concept:C0020541lld:lifeskim
pubmed-article:11516479lifeskim:mentionsumls-concept:C0037083lld:lifeskim
pubmed-article:11516479lifeskim:mentionsumls-concept:C1623038lld:lifeskim
pubmed-article:11516479pubmed:issue3lld:pubmed
pubmed-article:11516479pubmed:dateCreated2001-8-22lld:pubmed
pubmed-article:11516479pubmed:abstractTextAbnormal vascular responsiveness to ligands has been frequently observed in cirrhosis and portal hypertension, but its existence is not proven. The signaling pathways in vascular smooth muscle cells (VSMCs) have been studied only in animal models of cirrhosis and portal hypertension. Emerging evidence suggests that active relaxation, expressed as augmented content or activity of effectors within the cyclic AMP signaling pathway and suppressed content or activity of effectors in the inositol 1,4,5-trisphosphate/1,2-diacylglycerol signaling pathway, may be occurring in VSMCs of the splanchnic circulation in portal hypertension. The evidence supporting the existence of this phenomenon in the VSMCs of extrasplanchnic circulations in portal hypertension, as well as in the splanchnic circulation when chronic cellular damage is present, is very limited. The status of the other signaling pathways associated with contractile functions of the VSMCs, viz., cyclic GMP and tyrosine kinase-linked pathways, is unknown. The status of all the signaling pathways in non-contractile functions of VSMCs, such as growth and remodeling, has not been studied. As our overall understanding on the signaling pathways in VSMCs is only emerging, it is premature to implicate altered activity of the signaling pathways as the underlying basis of vascular hyporesponsiveness in cirrhosis and portal hypertension, and to extrapolate these limited observations to the human condition.lld:pubmed
pubmed-article:11516479pubmed:languageenglld:pubmed
pubmed-article:11516479pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11516479pubmed:citationSubsetIMlld:pubmed
pubmed-article:11516479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11516479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11516479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11516479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11516479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11516479pubmed:statusMEDLINElld:pubmed
pubmed-article:11516479pubmed:monthMarlld:pubmed
pubmed-article:11516479pubmed:issn0163-7258lld:pubmed
pubmed-article:11516479pubmed:authorpubmed-author:HuangY TYTlld:pubmed
pubmed-article:11516479pubmed:authorpubmed-author:BomzonAAlld:pubmed
pubmed-article:11516479pubmed:issnTypePrintlld:pubmed
pubmed-article:11516479pubmed:volume89lld:pubmed
pubmed-article:11516479pubmed:ownerNLMlld:pubmed
pubmed-article:11516479pubmed:authorsCompleteYlld:pubmed
pubmed-article:11516479pubmed:pagination255-72lld:pubmed
pubmed-article:11516479pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:meshHeadingpubmed-meshheading:11516479...lld:pubmed
pubmed-article:11516479pubmed:year2001lld:pubmed
pubmed-article:11516479pubmed:articleTitleVascular smooth muscle cell signaling in cirrhosis and portal hypertension.lld:pubmed
pubmed-article:11516479pubmed:affiliationDepartment of Pharmacology, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, P.O. Box 9649, Haifa 31096, Israel. bomzon@tx.technion.ac.illld:pubmed
pubmed-article:11516479pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11516479pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11516479pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:11516479pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11516479lld:pubmed